tiopronin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	2676	1953-02-2

Description:

Molecule

Description

Molfile Inchi Smiles

Synonyms:

tiopronin
(+/-)-Tiopronin
acadione
capen
captimer
hepadigest
mercaptopropionylglycine
thiolpropionamidoacetic acid
thiopronin
thiopronine
tiopronine
alpha-Mercaptopropionylglycine

Sulfhydryl acylated derivative of GLYCINE.

Molecular weight: 163.19
Formula: C5H9NO3S
CLOGP: -0.24
LIPINSKI: 0
HAC: 4
HDO: 2
TPSA: 66.40
ALOGS: -1.60
ROTB: 3

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
0.80	g	O

ADMET properties:

Property	Value	Reference
BA (Bioavailability)	63 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	1.39 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	1.48 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.45 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	55 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
Aug. 11, 1988	FDA	MISSION PHARMA

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Nephrotic syndrome	47.15	38.21	10	218	9557	64488947

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	G04BX16	GENITO URINARY SYSTEM AND SEX HORMONES UROLOGICALS UROLOGICALS Other urologicals
FDA CS	M0289359	N-substituted Glycines
FDA MoA	N0000175549	Cystine Disulfide Reduction
FDA EPC	N0000175898	Reducing and Complexing Thiol

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Cystinuria	indication	85020001	DOID:9266
Cystine Renal Calculi	indication
Agranulocytosis	contraindication	17182001	DOID:12987
Proteinuria	contraindication	29738008	DOID:576
Goodpasture's syndrome	contraindication	50581000
Nephrotic syndrome	contraindication	52254009	DOID:1184
Leukopenia	contraindication	84828003	DOID:615
Kidney disease	contraindication	90708001	DOID:557
Myasthenia gravis	contraindication	91637004	DOID:437
Hypoalbuminemia	contraindication	119247004
Disease of liver	contraindication	235856003	DOID:409
Pregnancy, function	contraindication	289908002
Thrombocytopenic disorder	contraindication	302215000	DOID:1588
Aplastic anemia	contraindication	306058006	DOID:12449
Breastfeeding (mother)	contraindication	413712001

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	3.57	acidic
pKa2	8.48	acidic
pKa3	13.03	acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Exclusivity date	Description
100MG	THIOLA	MISSION PHARMA	N019569	Aug. 11, 1988	RX	TABLET	ORAL	June 28, 2026	INDICATED IN COMBINATION WITH HIGH FLUID INTAKE, ALKALI, AND DIET MODIFICATION, FOR THE PREVENTION OF CYSTINE STONE FORMATION IN PEDIATRIC PATIENTS 20KG TO 9 YEARS OF AGE W/SEVERE HOMOZYGOUS CYSTINURIA, WHO ARE NOT RESPONSIVE TO THESE MEASURES ALONE

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Angiotensin-converting enzyme	Enzyme		ACE_RABIT		IC50	5.72		CHEMBL

External reference:

ID	Source
4019475	VUID
N0000147595	NUI
D01430	KEGG_DRUG
4019475	VANDF
C0025405	UMLSCUI
CHEBI:32229	CHEBI
WJZ	PDB_CHEM_ID
CHEMBL1314	ChEMBL_ID
DB06823	DRUGBANK_ID
D008625	MESH_DESCRIPTOR_UI
5483	PUBCHEM_CID
3574	INN_ID
C5W04GO61S	UNII
6765	RXNORM
190283	MMSL
5587	MMSL
d01418	MMSL
002371	NDDF
109106000	SNOMEDCT_US
397225004	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Tiopronin	HUMAN PRESCRIPTION DRUG LABEL	1	0093-7909	TABLET, SUGAR COATED	100 mg	ORAL	ANDA	22 sections
Thiola	HUMAN PRESCRIPTION DRUG LABEL	1	0178-0900	TABLET, SUGAR COATED	100 mg	ORAL	NDA	15 sections
Thiola EC	HUMAN PRESCRIPTION DRUG LABEL	1	0178-0901	TABLET, DELAYED RELEASE	300 mg	ORAL	NDA	25 sections
Thiola EC	HUMAN PRESCRIPTION DRUG LABEL	1	0178-0902	TABLET, DELAYED RELEASE	100 mg	ORAL	NDA	25 sections